Targeting Bruton's tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study.

ABSTRACT: Vitreoretinal lymphoma (VRL) is strongly linked to central nervous system (CNS) progression with no standard treatment approaches. Commonly used strategies include repeated intraocular injections of low-dose methotrexate or local radiotherapy, with great inconvenience, long-term side effects, and high risk of CNS relapse. In this study, we evaluated the efficacy and safety of bruton's tyrosine kinase inhibitors (BTKi) in the treatment of VRL. This prospective single-center study enrolled patients with relapsed or newly diagnosed VRL between October 2020 and April 2022. Patients received BTKi monotherapy until disease progression or unacceptable toxicity. The primary endpoint was the disease control (DC) rate after one month of treatment; secondary endpoints include toxicity, overall surviv

SUBMITTER: Guan W 

PROVIDER: S-EPMC9644621 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature